Presented By Daniel Renouf at 2021 Gastrointestinal Cancers … · 2021. 1. 19. · Secondary endpoints: PFS Safety and toxicity • ORR Tertiary endpoints: QoL Correlative studies
Post on 10-Feb-2021
4 Views
Preview:
Transcript
Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
Background:
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
Slide 3
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
Slide 4
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
Slide 5
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
Slide 6
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
top related